

GSK'165: anti-GM-CSF antibody

A novel mechanism with potentially differentiated impact on pain in the treatment of Rheumatoid Arthritis

23 October 2018

Cautionary statement regarding forward-looking statements



This presentation may contain forward-looking statements. Forward-looking statements give the Group's current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as 'anticipate', 'estimate', 'expect', 'intend', 'will', 'project', 'plan', 'believe', 'target' and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results.

Other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulations, UK Listing Rules and the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority), the Group undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Investors should, however, consult any additional disclosures that the Group may make in any documents which it publishes and/or files with the US Securities and Exchange Commission (SEC). All investors, wherever located, should take note of these disclosures. Accordingly, no assurance can be given that any particular expectation will be met and investors are cautioned not to place undue reliance on the forward-looking statements.

Forward-looking statements are subject to assumptions, inherent risks and uncertainties, many of which relate to factors that are beyond the Group's control or precise estimate. The Group cautions investors that a number of important factors, including those in this presentation, could cause actual results to differ materially from those expressed or implied in any forward-looking statement. Such factors include, but are not limited to, those discussed under Item 3.D 'Risk factors' in the Group's Annual Report on Form 20-F for FY 2017. Any forward-looking statements made by or on behalf of the Group speak only as of the date they are made and are based upon the knowledge and information available to the Directors on the date of this presentation.

All expectations and targets regarding future performance should be read together with "Assumptions related to 2018 guidance and 2016-2020 outlook" on page 40 of our second quarter 2018 earnings release.

Agenda



GSK'165: anti-GM-CSF antibody Dr Hal Barron Chief Scientific Officer and President R&D		
Results of BAROQUE Phase 2 study Dr Roy Fleischmann Clinical Professor of Medicine at the University of Texas Southwestern Medical Center	Presentation	Q&A
RA market and commercial opportunity Luke Miels President, Global Pharmaceuticals	20-25 mins	20-25 mins
Q&A Dr Mark Layton Medicine Development Lead, GSK'165		

Rheumatoid Arthritis (RA): a chronic and debilitating inflammatory disease

Disease background

- RA is an autoimmune disease which causes inflammation in the joints and • results in pain, swelling and stiffness
- Estimated prevalence^{1,2}: ٠
 - Global: 24.5 million (~1% of 18+ world population)
 - US: 2.7 million
 - EU5: 2.6 million
 - Japan: 0.8 million
- Incidence is three times higher in women than men with peak onset • typically between the ages of 30 and 50 years³
- RA results in significant disability and increased mortality, largely due to • accelerated cardiovascular disease






4



Recent progress with new treatment options, but unmet need remains





New biologic therapies have improved treatment of RA, reducing symptoms and signs of the disease and reducing the progression of structural damage to joints in a subset of patients

Substantial unmet need remains


- Most effective current therapies only achieve
 ~50% disease improvement in <50% of patients
- Even with multiple targeted therapies only 30% of patients achieve remission
- ~50% of patients do not achieve low disease activity criteria within 12 months of aTNF treatment and ~80% do not achieve Disease Activity Score 28 remission
- 45% of patients report daily pain and pain is the key driver in 25% of switches biological and oral therapies

Sources: Targeted treatments for rheumatoid arthritis, Novel treatment strategies in rheumatoid arthritis, Gerd R Burmester, Janet E Pope; Adelphi RA DSP 2016 5

GSK'165 (aGM-CSF): potential for a disease modifying effect in rheumatoid arthritis (RA) with a unique impact on pain



The target	 GM-CSF is a pro-inflammatory cytokine that induces differentiation and proliferation of granulocytes and macrophages One of the first cytokines detected in human synovial fluid from inflamed joints Preclinical data suggests a broader range of actions than existing biologics (including a beneficial effect on pain)
The agent	 GSK'165 is a human antibody targeting anti-granulocyte macrophage colony-stimulating factor (aGM-CSF) Administration will likely be weekly via a subcutaneous injection with a choice of autoinjector or prefilled syringe
Current status	 Encouraging Phase 2 results in RA presented at ACR October 2018 Discussions with regulators planned to advance development rapidly in RA Exploration of additional indications beyond RA



Strong rationale for moving forward PAIN Central inhibition of granulocyte-macrophage colony-stimulating factor is analgesic in experimental neuropathic pain Louise S.C. Nicol[®], Peter Thomton[®], Jon P. Hatcher^b, Colin P. Glover[®], Carl I. Webste Grandorada macronhana colone eti a key mediator in inflammatory and arthritic pain Wealth of preclinical data in multiple animal models, Strong preclinical Research article including evidence specific to pain¹ Blockade of collagen-induced arthritis post-onset by data granulocyte-macrophage colony-stimulating factor ((requirement for GM-CSF in the effector phase of disc Andrew D Cook, Emma L Braine, Ian K Campbell*, Melissa J Rich and John A H Arthritis and Inflammation Research Centre, Department of Medicine, University of Melbourne, Parkville, Victoria, Australia Current address: Autoimmunity and Transplantation Division, The Walter and Eliza Hall Institute, Parkville, Victoria, Austra Correspondence: Dr Andrew Cook, Arthritia and Inflammation Research Centre, Department of Medicine, University of Australia, Tel: +61 3 8344 6252; far: +61 3 9347 1863; e-mail: adcock@unimelb.edu.au Interesting GM-CSF upregulates CCL17 production in human monocytes and macrophages AND is required for GM-CSF dependent arthritic pain and disease² biology DAS 28 (CRP) improvement in efficacy was statistically significant at Week 12 and Week 24 Endpoint most relevant to patients met at 12 weeks: ACR 20: % difference 40.5% (21.6, 59.5); Odds ratio 8.23 (2.41, 28.04) p<0.001 Compelling Swollen Joint Count 66: -7.54 (-11.78, -3.30); p<0.001) Tender Joint Count 68: -8.91 (-14.72, -3.10); p=0.003 clinical data Simple disease activity index (SDAI): -16.86 (-24.39, -9.32); p<0.001 Clinical disease activity index (CDAI): -16.63 (-23.97, -9.30); p<0.001

DAS28(CRP) <2.6 (remission) at 24 weeks was not statistically significant

Sources: 1. Avci et al, 2016; Wicks et al, 2016); Cook et al, 2001; Plater-Zyberk et al, 2007; Cook et al, 2012 & 2013; Achuthan et al, 2016; Cook et al, 2012, 2013 & 2018; Schweizerhof et al, 2009; Nicol et al, 2018 2. Achuthan et al, 2016; Cook et al, 2018; Lee et al, 2018



Key data demonstrating efficacy of GSK'165 aGM-CSF from the BAROQUE Phase 2 study


Presented at ACR 22 October 2018

Phase 2 study design

A randomised, multicentre, double-blind, parallel group, placebo controlled study with novel features to support a 52 week study



GSK3196165 or placebo administered as 5 weekly SC injections, followed by every other week injections



ACR, American College of Rheumatology; DAS28(CRP), Disease Activity Score for 28 different joints with C-reactive protein value; IR, incomplete responder; MTX, methotrexate; R, randomization; SC, subcutaneous; SJC, swollen joint count; TJC, tender joint count.

Baseline patient demographic characteristics

Typical, established RA MTX-IR population; well balanced across treatment groups



		GSK3196165 + MTX						
	Placebo + MTX (n=37)	22.5mg (n=37)	45mg (n=37)	90mg (n=37)	135mg (n=37)	180mg (n=37)		
Age (y), mean (SD)	50.0 (11.33)	48.4 (11.31)	52.8 (12.22)	52.7 (11.28)	47.1 (10.04)	52.3 (10.76)		
Female, n (%)	28 (76)	30 (81)	33 (89)	27 (73)	33 (89)	29 (78)		
RA diagnosis (mo), mean (SD)	73.8 (94.98)	75.3 (81.93)	61.3 (76.25)	73.1 (71.63)	82.3 (67.58)	85.9 (79.12)		
ACPA positive, n (%)	28 (76)	24 (65)	24 (65)	23 (62)	28 (76)	30 (81)		
RF positive, n (%)	28 (76)	26 (70)	27 (73)	21 (57)	22 (59)	30 (81)		
MTX (mg/week), mean (SD)	15.27 (3.475)	15.84 (4.313)	16.55 (4.270)	15.34 (3.688)	15.90 (3.213)	16.10 (3.268)		
Oral glucocorticoid use, n (%)	15 (41)	24 (65)	20 (54)	22 (59)	21 (57)	22 (59)		
Oral glucocorticoid dose (prednisolone equivalent mg/day), mean (SD)	6.37 (2.108)	6.04 (2.918)	6.83 (2.597)	6.75 (3.020)	5.90 (3.231)	5.89 (2.737)		

Baseline RA disease characteristics


gsk

Well balanced but with high DAS28(CRP) and HAQ-DI

		GSK3196165 + MTX							
	Placebo + MTX (n=37)	22.5mg (n=37)	45mg (n=37)	90mg (n=37)	135mg (n=37)	180mg (n=37)			
DAS28(CRP), mean (SD)	6.2 (0.82)	6.4 (0.82)	6.1 (0.74)	6.2 (0.84)	6.3 (0.92)	6.0 (0.88)			
SDAI (0–86), mean (SD)	47.4 (13.34)	48.0 (12.916)	45.2 (11.95)	46.5 (13.0)	48.2 (14.57)	44.4 (14.00)			
CDAI (0–76), mean (SD)	45.7 (13.46)	45.2 (11.81)	42.8 (12.10)	44.5 (12.57)	45.3 (13.50)	42.5 (13.90)			
TJC68, mean (SD)	28.5 (13.59)	27.9 (12.13)	26.1 (14.09)	28.8 (14.76)	30.1 (14.80)	25.3 (12.35)			
SJC66, mean (SD)	18.5 (9.29)	17.7 (8.53)	17.2 (8.94)	18.3 (10.05)	18.9 (10.15)	18.9 (10.11)			
Pain (100 mm VAS), mean (SD)	66.1 (16.68)	71.2 (15.84)	70.1 (17.27)	65.8 (20.38)	67.1 (19.27)	61.6 (20.62)			
PtGA (100 mm VAS), mean (SD)	66.0 (15.64)	72.5 (14.21)	71.6 (14.90)	68.2 (17.59)	69.6 (16.96)	63.2 (16.64)			
PhGA (100 mm VAS), mean (SD)	64.2 (11.88)	67.5 (10.27)	67.1 (15.86)	65.9 (18.58)	67.2 (15.37)	64.1 (5.72)			
HAQ-DI, mean (SD)	1.77 (0.592)	1.72 (0.482)	1.88 (0.405)	1.73 (0.544)	1.80 (0.564)	1.63 (0.706)			
hsCRP (mg/mL), median (range)	12.9 (2–66)	19.5 (3–135)	14.7 (1–158)	13.7 (1–99)	15.6 (1–261)	12.7 (2–103)			


CDAI, Clinical Disease Activity Index; DAS28, Disease Activity Score 28-joint count; HAQ-DI, Health Assessment Questionnaire Disability Index; hsCRP, high-sensitivity C-reactive protein; PhGA, Physician's Global Assessment of Arthritis; PtGA, Patient's Global Assessment of Arthritis Disease Activity; SDAI, Simplified Disease Activity Index; SJC66, swollen joint count for 66 different joints; TJC68, tender joint count for 68 different joints; VAS, visual analogue scale.

Rationale for weekly dosing going forward



Patient disposition on randomised treatment

70% of placebo patients switched to GSK'165 180mg dose at Wk12 early escape point



Escape criteria: EULAR Response (moderate/ good) at weeks 12 and 24 to 180mg dose


SF, screening failure; W, week.

gsk

Significantly higher response rates at Week 12 with GSK'165 versus placebo

gsk

ACR 20 at Week 12




*P<0.05; **P<0.01; ***P<0.001 versus placebo. GSK3196165 versus placebo: OR (95% CI): 8.23 (2.41, 28.04); p<0.001. ACR, American College of Rheumatology; CI, confidence interval; OR, odds ratio.

14

Rapid onset of action during weekly dosing phase


Clinical Response: DAS28(CRP) and DAS28(CRP) <2.6



Repeated measures analysis adjusted for DAS28(CRP) baseline score, treatment group, visit and treatment group by visit and baseline by visit interactions. Data post Week 24 were excluded due to quantity of missing data. Values on graph are LS mean change from BL at W4, W12 and W24. *P<0.05; **P<0.01; ***P<0.001 versus placebo. BL, baseline; CI, confidence interval; CRP, C-reactive protein; D, day; DAS28, disease activity score for 28 different joints; DAS28(CRP), DAS28 with CRP value; EOW, every other week; LS, least squares; SE, standard error; ITT, intent to treat; W, week.

Rapid and substantial improvement in joint counts


Swollen Joint Count (SJC) 66 & Tender Joint Count (TJC) 68



Repeated measures analysis adjusted for baseline, treatment group, visit and treatment group by visit and baseline by visit interactions. Values on graph are LS mean change from BL at W4 and W12. *P<0.05; **P<0.01; ***P<0.001 versus placebo. BL, baseline; LS, least squares; SE, standard error; SJC66, swollen joint count for 66 different joints; TJC68, tender joint count for 68 different joints; W, week.

16


Rapid and substantial improvement in pain, CRP reduced but not suppressed



Repeated measures analysis adjusted for baseline, treatment group, visit and treatment group by visit and baseline by visit interactions. Values on graph are LS mean change from BL (pain score) or LS mean ratio to BL (CRP) at W4 and W12. *P<0.05; **P<0.01; ***P<0.001 versus placebo. BL, baseline; CI, confidence interval; CRP, C-reactive protein; LS, least squares; SE, standard error; W, week.

Marked clinical response on Clinical Disease Activity Index (CDAI)





Repeated measures analysis adjusted for baseline, treatment group, visit and treatment group by visit and baseline by visit interactions. Values on graph are LS mean change from BL at W4 and W12. *P<0.05; **P<0.01; ***P<0.001 versus placebo. BL, baseline; CDAI, Clinical Disease Activity Index; CI, confidence interval; LS, least squares; SE, standard error; W, week.

Totality of data supports further studies

Benefits across multiple endpoints, notably in pain and swollen and tender joint counts

	Placebo + MTX (n=37)	GSK3196165 180 mg + MTX (n=37)	
Clinical endpoint at Week 12	LS mean change f	rom baseline (SE)	Difference from placebo (95% Cl); p-value
DAS 28(CRP)	-0.60 (0.23)	-1.87 (0.23)	-1.27 (-1.91, -0.63); p<0.001
CDAI	-6.59 (2.66)	-23.23 (2.60)	-16.63 (-23.97, -9.30); p<0.001
Pain	-7.07 (3.71)	-25.01 (3.65)	-17.94 (-28.18, -7.70); p<0.001
HAQ-DI	-0.26 (0.09)	-0.50 (0.09)	-0.24 (-0.49, 0.01); p=0.059
Patient's Global Assessment of Arthritis	-6.72 (3.66)	-23.9 (3.61)	-17.18 (-27.27, -7.10); p<0.001
SJC66	-3.70 (1.54)	-11.24 (1.51)	-7.54 (-11.78, -3.30); p<0.001
TJC68	-4.49 (2.10)	-13.41 (2.07)	-8.91 (-14.72, -3.10); p=0.003
	Respond	ers, n (%)	
ACR20	4 (11)	19 (51)	40.5% (21.6, 59.5); p<0.001
ACR50	3 (8)	8 (22)	13.5% (-2.4, 29.4); p=0.134
Good/moderate EULAR	8 (22)	28 (76)	54.1% (34.9, 73.2); p<0.001

ACR, American College of Rheumatology; CDAI, Clinical Disease Activity Index; CI, confidence interval; DAS28(CRP), Disease Activity Score for 28 different joints with C-reactive protein value; EULAR, European League Against Rheumatism; HAQ-DI, Health Assessment Questionnaire - Disability Index; LS, least squares; SE, standard error; SJC66, swollen joint count for 66 different joints; TJC68, tender joint count for 68 different joints.



Overall AE profile unremarkable: majority were of mild or moderate intensity



		GSK3196165 + MTX						GSK3196165 + MTX				
Pre-rescue, n (%)	Placebo + MTX (n=37)	22.5mg (n=37)	45mg (n=37)	90mg (n=37)	135mg (n=37)	180mg (n=37)	Post rescue, n (%)	Placebo + MTX (n=33)	22.5mg (n=30)	45mg (n=27)	90mg (n=25)	135mg (n=28)
Any AES	18 (49)	19 (51)	24 (65)	22 (59)	19 (51)	24 (65)	Any AEs	22 (67)	16 (53)	11 (41)	10 (40)	17 (61)
SAEs	0 (0)	2 (5)	1 (3)	2 (5)	1 (3)	0 (0)	SAEs	1 (3)	0 (0)	0 (0)	0 (0)	1 (4)
Treatment-related AEs	2 (5)	9 (24)	6 (16)	6 (16)	5 (14)	9 (24)	Treatment-related AEs	5 (15)	6 (20)	4 (15)	0 (0)	6 (21)
Withdrawal due to AEs	0 (0)	0 (0)	0 (0)	2 (5)	0 (0)	2 (5)	Withdrawal due to AEs	1 (3)	1 (3)	0 (0)	0 (0)	0 (0)
Total exposure, patient-years	11.6	14.4	18.3	19.5	16.8	32.0	Total exposure, patient-years	19.6	16.0	15.2	13.9	14.6

Pre-rescue

There were no deaths, malignancy or venous thromboembolism during the trial

Post-rescue




RA market and commercial opportunity

Luke Miels, President, Global Pharmaceuticals

Evolving treatment paradigm provides opportunity for new mechanisms of action






RA market growth to be driven by new mechanisms



RA market decline due to biosimilars; value opportunity for new MOA's



Annual WW RA sales, £m¹

Opportunity for alternative mechanisms of action

Importance of demonstrating differentiated efficacy

Note: "Other" includes COX inhibitor, GCR agonist, MC2 agonist etc.

Strong rationale for moving forward



Data supports further development	 Exciting asset with a novel mechanism of action which has shown compelling data across traditional endpoints for RA supporting further and accelerated clinical development
Next steps	 Plans for discussions with regulators with a view to rapidly advancing development
Life cycle management	 Explore potential efficacy of GSK'165 in additional indications



